Premium
RESULTS OF PHASE II STUDY OF COMBINED IMMUNOTHERAPY WITH RITUXIMAB PLUS LYMPHOKINE‐ACTIVATED KILLER CELLS AS MAINTENANCE IN FOLLICULAR LYMPHOMA PATIENTS
Author(s) -
Martinez Calle N.,
Diaz De Cerio A.,
Pena E.,
Garcia Muñoz R.,
Panizo A.,
Feliu J.,
Giraldo P.,
Rodriguez M.,
Grande C.,
Olave T.,
AndradeCampos M.,
Bandres E.,
Nuñez J.,
Inoges S.,
Panizo C.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.192_2631
Subject(s) - antibody dependent cell mediated cytotoxicity , medicine , rituximab , cd20 , peripheral blood mononuclear cell , immunology , lymphokine activated killer cell , lymphokine , cytotoxic t cell , follicular lymphoma , monoclonal antibody , lymphoma , antibody , antigen , immune system , t cell , interleukin 21 , biology , in vitro , biochemistry
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom